Making informed investment decisions (Attracting breakthrough innovations from academic research) - SPRIND case study

SPRIND GmbH, the German Federal Agency for Disruptive Innovation, was exploring investments in highly innovative ideas including start-up biotech and needed third-party assistance evaluating assets/technologies, including IP strength, to determine investment viability. Clarivate's preliminary engagement provided disease landscape reports covering key oncology indications (prostate and lung cancer), enabling an initial cost-effective analysis, and Clarivate's consulting team went on to evaluate a potential investment in an innovative start-up biotech. The partnership let SPRIND make informed investment decisions using best-in-class reports and unbiased third-party valuations, and it continues as an ongoing relationship for future valuation requests. No specific dollar figures or investment outcomes are disclosed.

Clarivate owns Cortellis, the curated competitive-intelligence and pipeline-tracking platform standard in pharma portfolio-management teams.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.